NCT01100502

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Nowotwór
chłoniak Hodgkina
Chorzy
po przeszczepie
Faza badania
III
Sponsor badania
Seattle Genetics
Termin
-
Linki
www.clinicaltrials.gov
Dane kontaktowe
Klinika Hematologii UCK Gdańsk,
Marcelina Paruch,
Ph: +48 22 210 02 00 (01) ext.4864, marcelina.paruch@psi-cro.com;
Gliwice; Katowice; Kraków; Lublin;Łódź; Warszawa